Given the prevalence of PIK3CA alterations in HNSCC and its dominant driving properties, understanding mechanisms of response and resistance to PI3K therapies is paramount for the future of precision medicine in these patients. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.